Takeda Recognized as a Global 100 Most Sustainable Corporation for Third Consecutive Year

The Index launched in 2005; results are disclosed annually at the World Economic Forum in Davos.

As a LEAD company within the United Nations Global Compact, Takeda’s established track record in sustainability is guided by long-term international targets such as the Sustainable Development Goals (SDGs). Takeda is the only Japanese pharmaceutical company and among the four companies from Japan to make the final 100 in 2018, and one of just ten pharmaceutical companies in the world to be listed.

“Takeda is honored to be recognized once again for our commitment to sustainability, particularly alongside such distinguished global corporations,” said Haruhiko Hirate, Corporate Communications & Public Affairs Officer. “We strive to create and maximize long-term economic, social, and environmental value worldwide, led by our unique and diverse corporate governance, through our corporate social responsibility (CSR), which contributes to the lasting health of patients worldwide through long-term investments in disease prevention, capacity building, and access to healthcare. As a company, Takeda strives for Better Health and a Brighter Future for people worldwide through leading innovation in medicine, together with the global community.”

In addition to the Global 100 Index, Takeda is recognized by multiple Socially Responsible Investment (SRI) valuations. 

Name of Index/Investment Universe/Ratings	Company/ Organization Conducting Assessment	Country	Honors Awarded
Dow Jones Sustainability Asia Pacific Index	S&P Dow Jones Indices	US	8th consecutive year
FTSE4Good Global Index	FTSE Russel	UK	13th consecutive year
Ethibel EXCELLENCE Investment Register	Forum Ethibel	BEL	three times
Prime Status	Oekom	GER	first time

About Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.

For more information, visit https://www.takeda.com/newsroom/.

Additional information about Takeda is available through its Sustainable Value Report.